       Document 0336
 DOCN  M94A0336
 TI    Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive
       patients.
 DT    9412
 AU    Geriniere L; Bastion Y; Dumontet C; Salles G; Espinouse D; Coiffier B;
       Service d'Hematologie, Centre Hospitalier Lyon-Sud, Pierre; Benite,
       France.
 SO    Ann Oncol. 1994 May;5(5):437-40. Unique Identifier : AIDSLINE
       MED/94355264
 AB    BACKGROUND: As opposed to large-cell or Burkitt's-type non-Hodgkin's
       lymphoma, acute lymphoblastic leukemia (ALL) is rarely observed in
       HIV-seropositive patients and is not a criteria of AIDS in the 1986
       classification established by the C.D.C. Furthermore, the few cases of
       ALL reported so far were B-cell ALL, Burkitt's-type. DESIGN: We recently
       observed, with unexpected frequency, ALL cases in this setting: over a
       5-year period, 5 of 25 HIV-positive patients referred to our center for
       hematological malignancies, had ALL. Three patients, who had previously
       been asymptomatic with regard to HIV infection, had typical
       Burkitt's-type ALL. Complete remission was achieved in all cases with
       high-dose lymphoma-type chemotherapy regimens, but 2 patients relapsed 3
       and 27 months after diagnosis. Their clinical characteristics and
       outcome are discussed with reference to the cases reported thus far in
       the literature. One patient had common early pre-B ALL with the
       Philadelphia chromosome, and one had a T-cell ALL with an unusual CD7+,
       CD4-, CD8- phenotype. Prognosis was very poor in both cases. CONCLUSION:
       The exact incidence and the therapeutic management of B-cell ALL in
       HIV-positive patients warrants further evaluation. In addition, we show
       that there may be a heterogeneity among ALL cases in this setting, with
       the first description of 2 non-Burkitt's ALL with atypical features in
       HIV-positive patients.
 DE    Adult  Antigens, CD/ANALYSIS  Antigens, Differentiation,
       T-Lymphocyte/ANALYSIS  Antineoplastic Agents, Combined/THERAPEUTIC USE
       Human  HIV Seropositivity/*COMPLICATIONS  Leukemia,
       CALLA-Positive/COMPLICATIONS  Leukemia, Lymphocytic,
       Acute/*COMPLICATIONS/DRUG THERAPY  Leukemia, Pre-B-Cell/COMPLICATIONS
       Leukemia, T-Cell, Acute/COMPLICATIONS/IMMUNOLOGY  Male  Prognosis
       JOURNAL ARTICLE  REVIEW  REVIEW OF REPORTED CASES

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

